Format

Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1162-5. doi: 10.1016/j.ijrobp.2008.12.054. Epub 2009 Mar 26.

Twenty-year survival in glioblastoma: a case report and molecular profile.

Author information

1
Minneapolis Radiation Oncology, Minneapolis, MN, USA. psperduto@mropa.com

Abstract

BACKGROUND:

The prognosis for patients with glioblastoma (GB) remains grim. Historically, the median survival has been 6 to 9 months. Recent research has improved the outcome slightly. A computer search of the literature reveals few long-term survivors.

METHOD:

Presented here is a case report of a 20-year survivor of GB, with pathologic review to confirm the diagnosis. A battery of molecular studies was performed to develop a molecular profile of this unique patient.

RESULTS:

The results of the molecular genetic testing for this most unusual patient were as follows: (1) methylguanine methyl transferase (MGMT) was methylated, (2) p53 positive, (3) PTEN tumor suppressor gene positive, (4) protein kinase AKT (pAKT) negative, and (5) epidermal growth factor receptor negative.

CONCLUSION:

To our knowledge, this is the longest survival of any patient in the literature whose initial diagnosis was GB. Triple-positive GBM patients (MGMT methylated, PTEN, and p53 positive) are uncommon but may be associated with a better prognosis. Further research is needed to confirm whether this molecular profile is prognostic of prolonged survival. Molecular genetics will determine future treatment and prognosis in GB.

PMID:
19327897
DOI:
10.1016/j.ijrobp.2008.12.054
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center